参考文献/References:
[1] Thurman DJ, Beghi E, Begley CE, et al. Standards for epidemiologic studies and surveillance of epilepsy[J]. Epilepsia, 2011, 52(7, SI): 2-26.
[2] Gu L, Liang B, Chen Q, et al. Prevalence of epilepsy in the People’s Republic of China: a systematic review[J]. Epilepsy Res, 2013, 105(1/2): 195-205.
[3] Mackenzie PI, Bock KW, Burchell B, et al. Nomenclature update for the mammalian UDP glycosyltransferase(UGT)gene superfamily[J]. Pharmacogenet Genomics, 2005, 15(10): 677-685.
[4] Lv X, Zhang JB, Hou J, et al. Chemical probes for human UDP-Glucuronosyltransferases: A comprehensive review[J]. Biotechnol J, 2019, 14(1): e1800002.
[5] Mackenzie PI, Rogers A, Elliot DJ, et al. The novel UDP glycosyltransferase 3A2: cloning, catalytic properties, and tissue distribution[J]. Mol Pharmacol, 2011, 79(3): 472-478.
[6] Rowland A, Miners JO, Mackenzie PI. The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification[J]. Int J Biochem Cell Biol, 2013, 45(6): 1121-1132.
[7] Oda S, Fukami T, Yokoi T, et al. A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development[J]. Drug Metab Pharmacokinet, 2015, 30(1): 30-51.
[8] 马春来.基因多态性对卡马西平及其衍生物奥卡西平药动学及药效学的影响[D].上海:复旦大学,2013.
[9] May TW, Korn-Merker E, Rambeck B.Clinical pharmacokinetics of oxcarbazepine[J]. Clin Pharmacokinet, 2003, 42(12): 1023-1042.
[10] Lu Y, Fang YX, Wu X, et al. Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy[J]. Eur J Clin Pharmacol, 2017, 73(3): 307-315.
[11] Shen C, Zhang BJ, Liu ZR, et al. Effects of ABCB1, ABCC2, UGT2B7 and HNF4α genetic polymorphisms on oxcarbazepine concentrations and therapeutic efficacy in patients with epilepsy[J]. Seizure, 2017, 51: 102-106.
[12] Yang X, Yan YL, Fang S, et al. Comparison of oxcarbazepine efficacy and MHD concentrations relative to age and BMI: Associations among ABCB1, ABCC2, UGT2B7, and SCN2A polymorphisms[J]. Medicine(Baltimore), 2019, 98(12): e14908.
[13] 周燕利,聂琼芳,唐今尧,等.CYP2C19*3基因多态性对癫痫患者奥卡西平活性代谢产物MHD浓度的影响[J].中国医院药学杂志,2019,39(14):1472-1475.
[14] 周鑫,马凌悦,向倩,等.癫痫患者细胞色素P450 2C19 * 2基因型与奥卡西平活性代谢物浓度相关性研究[J].中国临床药理学杂志,2017,33(7):595-598.
[15] Wang P, Yin T, Ma HY, et al. First analysis of the association between CYP3A4/5, ABCB1 genetic polymorphisms and oxcarbazepine metabolism and transport in Chinese epileptic patients with oxcarbazepine monotherapy and bitherapy[J]. J Pharm Pharm Sci, 2015, 18(3): 256-265.
[16] 岳丽.ABCB1基因多态性在癫痫患者中的分布及其与抗癫痫药物疗效的相关性研究[D].上海:复旦大学,2010.
[17] Manna I, Gambardella A, Bianchi A, et al. A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy[J]. Epilepsia, 2011, 52(5): e40-e44.
[18] Ghodke-Puranik Y, Thorn CF, Lamba JK, et al. Valproic acid pathway: pharmacokinetics and pharmacodynamics[J]. Pharmacogenet Genomics, 2013, 23(4): 236-241.
[19] Chateauvieux S, Morceau F, Dicato M, et al. Molecular and therapeutic potential and toxicity of valproic acid[J]. J Biomed Biotechnol, 2010: 479364.
[20] Hung CC, Ho JL, Chang WL, et al. Association of genetic variants in six candidate genes with valproic acid therapy optimization[J]. Pharmacogenomics, 2011, 12(8): 1107-1117.
[21] Guo Y, Hu C, He X, et al. Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy[J]. Drug Metab Pharmacokinet, 2012, 27(5): 536-542.
[22] 林雪玉,张燕青,林鹏锋,等.UGT1A6、UGT1A9基因多态性对汉族癫痫患者丙戊酸血药浓度的影响[J].中国药房,2017,28(8):1013-1017.
[23] Kim SC, Kim MG. A meta-analysis of the influence of UGT1A6 genetic polymorphisms on valproic acid pharmacokinetics[J]. Int J Clin Pharmacol Ther, 2019, 57(3): 144-151.
[24] 孙银香,卓文燕,林虹,等.UGT2B7 C802T和G211T基因多态性对癫痫患者丙戊酸代谢的影响[J].中国医院药学杂志,2015,35(3):216-219.
[25] Zhang H, Zhang W, Li YE, et al. Correlations between UGT2B7*2 gene polymorphisms and plasma concentrations of carbamazepine and valproic acid in epilepsy patients[J]. Brain Dev, 2018, 40(2): 100-106.
[26] 马虹英,张婷,龚志成,等.UGT2B7基因多态性对丙戊酸血药浓度的影响(英文)[J].中南大学学报:医学版,2013,38(08):766-772.
[27] Inoue K, Suzuki E, Yazawa R, et al. Influence of uridine diphosphate glucuronosyltransferase 2B7 -161C>T polymorphism on the concentration of valproic acid in pediatric epilepsy patients[J]. Ther Drug Monit, 2014, 36(3): 406-409.
[28] 张蒙.癫痫患儿UGT1A3基因多态性与丙戊酸钠血药浓度相关性研究[D].衡阳:南华大学,2019.
[29] Yasam VR, Jakki SL, Senthil V, et al. A pharmacological overview of lamotrigine for the treatment of epilepsy[J]. Expert Rev Clin Pharmacol, 2016, 9(12): 1533-1546.
[30] Chang Y, Yang LY, Zhang MC, et al. Correlation of the UGT1A4 gene polymorphism with serum concentration and therapeutic efficacy of lamotrigine in Han Chinese of Northern China[J]. Eur J Clin Pharmacol, 2014, 70(8): 941-946.
[31] Gulcebi MI, Ozkaynakc A, Goren MZ, et al. The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy[J]. Epilepsy Res, 2011, 95(1/2): 1-8.
[32] Reimers A, Sjursen W, Helde G, et al. Frequencies of UGT1A4*2(P24T)and *3(L48V)and their effects on serum concentrations of lamotrigine[J]. Eur J Drug Metab Pharmacokinet, 2016, 41(2): 149-155.
[33] Kim SC, Kim MG. Meta-analysis of the Influence of UGT Genetic Polymorphisms on Lamotrigine Concentration[J]. Basic Clin Pharmacol Toxicol, 2019, 124(2): 163-169.
[34] Staines AG, Coughtrie MW, Burchell B. N-glucuronidation of carbamazepine in human tissues is mediated by UGT2B7[J]. J Pharmacol Exp Ther, 2004, 311(3): 1131-1137.
[35] Lu Q, Huang YT, Shu Y, et al. Effects of CYP3A5 and UGT2B7 variants on steady-state carbamazepine concentrations in Chinese epileptic patients[J]. Medicine(Baltimore), 2018, 97(30): e11662.
[36] Hung CC, Chang WL, Ho JL, et al. Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization[J]. Pharmacogenomics, 2012, 13(2): 159-169.